Clinical Trials Browser

Phase 1/2 × Leukemia, Myelomonocytic, Chronic × ruxolitinib × Clear all

NCT07128381 2026-01-05

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Phase 1/2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT01776723 2022-09-22

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Phase 1/2 Completed

50 enrolled 17 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myelomonocytic, Chronic